5 Undervalued Stocks to Buy in November 2024

• 0:00 Introduction: The video focuses on 5 undervalued stock picks for November 2024, chosen after companies reported their earnings.
• 0:37 HIMS (Hims & Hers Health, Inc.): A telehealth platform for personalized prescriptions (hair loss, weight, anxiety, skin, sexual health).
  • Strong growth: Revenue up 77% year-over-year, accelerating to 90% projected growth in the next quarter.
  • Profitable: Generating tens of millions in free cash flow quarterly, with potential for higher profitability if marketing expenses were reduced.
  • High customer retention: 85% long-term customer retention.
  • Concerns: Share dilution (up 12% year-over-year) and potential competition from Amazon.
  • Valuation: Trading at 13x free cash flow, considered cheap for a high-growth company.
• 10:08 EVV (Evolution AB): A B2B provider for online casinos, offering live casino games, slots, etc.
  • Solid but slowing growth: Net revenue up 15% year-over-year (adjusted for one-time items), with growth slowing in recent quarters.
  • Profitable: EBITA margin of 68.5%, though slightly down year-over-year.
  • Concerns: Slowing revenue and game rounds played, potentially indicating market saturation.
  • Valuation: Trading at 16x free cash flow with a 6.33% free cash flow yield, priced as a slow-growth company.
• 16:50 LNTH (Lantheus Holdings, Inc.): A radiopharmaceutical company focused on diagnostic imaging.
  • Growth driven by new product: Significant growth fueled by the launch of Pylarify, a prostate cancer imaging agent.
  • Strong financials: Cash position nearly equals total liabilities.
  • Concerns: Growth is slowing as Pylarify saturates its target market. Future growth depends on developing and launching new products.
  • Valuation: Trading at 14.1x free cash flow with a 7% free cash flow yield, suggesting limited growth expectations.
• 23:40 MELI (MercadoLibre, Inc.): An e-commerce and fintech giant in Latin America.
  • Continued high growth: Revenue up 35% year-over-year, reaching new all-time highs.
  • Highly profitable: Free cash flow at an all-time high of $6.2 billion.
  • Strong moat: Believed to have a durable competitive advantage.
  • Valuation: Trading at 15.4x free cash flow with a 6.5% free cash flow yield, considered undervalued given its growth.
• 25:21 BN (Brookfield Corporation): A global alternative asset manager.
  • High-quality business: Strong track record of growth and profitability.
  • Attractive valuation: Believed to be trading below intrinsic value.
  • Bill Ackman's endorsement: Recently increased his position, making BN his second largest holding.
  • Continued buying: The video creator is also continuing to add to his BN position.
• 27:28 Conclusion: The video concludes by encouraging viewers to like and subscribe, and to check out links in the description for more information.

Error: value error